FDA nod for acoltremon: What its approval means for clinicians and patients
Author(s): Sheryl Stevenson Alcon’s announcement of the FDA approval for its acoltremon ophthalmic solution 0.003% (Tryptyr; formerly AR-15512) for the treatment of signs and symptoms of dry eye disease (DED)1,2 brings…